Biotechnology News

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. The Company today announced that, effective on October 15, 2026, it granted stock options to purchase shares of common stock to Stephen Aschettino, the Com...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK; the “Company”) today announced that the Company granted inducement equity awards covering an aggregate of 61,020 shares of its common stock to seven newly hired employees, consisting of inducement stock options to purchase an aggregate of 17,461 shares of common stock and inducement restricted stock units, covering an aggregate of 43,559 shares of its common stock. The awards are subject to all terms and conditions and other provisi...

PARAMUS, N.J.--(BUSINESS WIRE)--Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company employing standard-of-care therapies with proprietary delivery technologies, announced today that Chief Medical Officer Dr. Jamie Oliver, Pharm.D., will participate as a panelist at BioFuture 2026, taking place Oct. 27-28, 2026, in New York. Dr. Oliver will join fellow industry leaders to discuss the technologies shaping what comes next across the life sciences, including oncology, CNS,...

CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced the publication of long-term data from the Phase 2/3 QUILT-3.032 study (N=100) in the Journal of Urology. The study evaluated ANKTIVA® (nogapendekin alfa inbakicept-pmln) in combination with Bacillus Calmette-Guérin (BCG) in patients with BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS), with or without papillary disease. Highl...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics today announced publication of its OncoPrism®-NSCLC clinical validation study in npj Precision Oncology, a peer-reviewed Nature Portfolio journal. The study represents the latest results from Cofactor’s multisite PREDAPT clinical trial and extends the clinical validation of the multidimensional RNA biomarker underlying OncoPrism-HNSCC—a clinically validated, Medicare-covered test for recurrent or metastatic head and neck squamous cell carcinoma—to a...

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, announced today that, on October 20, 2026, the Company will implement a 1-for-7 reverse split of its common stock. The reverse stock split will be effective as of the morning of October 20, 2026, and the Company’s common stock will trade on a post-split basis at the beginning of trading...

PHOENIX--(BUSINESS WIRE)--Following yesterday’s milestone launch announcement, EmeraNova™, the new corporate identity of BioLab Holdings and a medical technology company building an advanced tissue restoration platform, has announced a collaboration that will expand its portfolio into an entirely new category and allow it to enter additional care settings. Technology leader Kent Imaging is teaming up with EmeraNova to bring advanced wound imaging to wound care clinics, surgical centers, hospita...

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced the publication of research conducted at the University of Michiganiv evaluating the use of End-tidal Control software across a large multisite academic health system in Anesthesia & Analgesia Practice. The retrospective observational study analyzed 12,818 adult general anesthesia cases performed at University of Michigan Health – Ann Arbor locations between April 1, 2023 and September 30, 2024 on anesthesia machines wit...

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets. Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabi...

TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEssentia Corporation (TWSE: 6446), a Taiwan-based biopharmaceutical company, is expanding its global presence through new drug approvals, clinical trials and overseas investments, as it seeks to bring its Taiwan-developed innovative new drug to more international markets. Founded in Taiwan in 2003 by scientist Dr. Ko-Chung Lin (林國鐘), with a commitment to developing innovative treatments for patients worldwide, PharmaEssentia has developed integrated capabi...